RBC Capital analyst Frank Morgan maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) Corp. on Thursday, setting a price target of $42, which is approximately 6.90% above the present share price of $39.29.
Morgan expects Fresenius Medical Care Corp . to post earnings per share (EPS) of $0.00 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Fresenius Medical Care, with an average price target of $42.93.
The analysts price targets range from a high of $46 to a low of $37.7.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $4.49 billion and a net profit of $510.39 million. The company's market cap is $23.05 billion.
According to TipRanks.com, RBC Capital analyst Frank Morgan is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 8.7% and a 60.00% success rate.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
